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AbstrAct
Introduction Effective chronic disease care is 
dependent on well-organised quality improvement (QI) 
strategies that monitor processes of care and outcomes 
for optimal care delivery. Although healthcare is 
provincially/territorially structured in Canada, there are 
national networks such as the Canadian Primary Care 
Sentinel Surveillance Network (CPCSSN) as important 
facilitators for national QI-based studies to improve 
chronic disease care. The goal of our study is to improve 
the understanding of how patients with chronic kidney 
disease (CKD) are managed in primary care and the 
variation across practices and provinces and territories 
to drive improvements in care delivery.
Methods and analysis The CPCSSN database 
contains anonymised health information from the 
electronic medical records for patients of participating 
primary care practices (PCPs) across Canada 
(n=1200). The dataset includes information on patient 
sociodemographics, medications, laboratory results 
and comorbidities. Leveraging validated algorithms, 
case definitions and guidelines will help define CKD 
and the related processes of care, and these enable us 
to: (1) determine prevalent CKD burden; (2) ascertain 
the current practice pattern on risk identification 
and management of CKD and (3) study variation in 
care indicators (eg, achievement of blood pressure 
and proteinuria targets) and referral pattern for 
specialist kidney care. The process of care outcomes 
will be stratified across patients’ demographics as 
well as provider and regional (provincial/territorial) 
characteristics. The prevalence of CKD stages 3–5 
will be presented as age–sex standardised prevalence 
estimates stratified by province and as weighted 
averages for population rates with 95% CIs using 
census data. For each PCP, age–sex standardised 
prevalence will be calculated and compared with 
expected standardised prevalence estimates. The 
process-based outcomes will be defined using 
established methods.
Ethics and dissemination The CPCSSN is committed 
to high ethical standards when dealing with individual 
data collected, and this work is reviewed and approved 
by the Network Scientific Committee. The results will 
be published in peer-reviewed journals and presented 
at relevant national and international scientific 
meetings.
IntroductIon
There is an absence of effective surveillance 
mechanisms for chronic kidney disease (CKD) 
in most countries despite the overwhelming 
opinion of key stakeholders supporting such 
developments.1 2 There are a few countries in 
the world with well-established CKD surveil-
lance systems (Australia, Japan, UK and 
USA).1 3 As with all other non-communicable 
diseases (NCDs), planning, development and 
implementation of effective and efficient 
care programs require reliable national data 
systems to monitor the burden of disease, 
processes of care and clinical outcomes.4–12 
Once established, these systems can be 
used for routine surveillance (including 
secular trends), quality improvement (QI) 
and resource allocation (including work-
force planning). In Canada, they would also 
allow for within-country comparisons across 
strengths and limitations of this study
 ► To our knowledge, this is the first nationwide and 
largest retrospective observational study on the 
epidemiology and management of chronic kidney 
disease  (CKD) in primary care in Canada with 
potential to identify opportunities for improving 
quality of care for CKD at a national level.
 ► It will define the practice patterns on CKD risk 
identification in primary care by ascertaining 
whether high-risk groups are appropriately tested, 
monitored and managed for CKD based on existing 
guideline recommendations.
 ► It will investigate the variation in CKD care delivery 
across patient, provider and regional characteristics, 
relative to established quality indicators.
 ► This study leverages retrospective data collated 
at point of care, and therefore, limitations include 
variable data quality and incomplete information in 
some data domains.
 ► The results of this study will enable the development 
of strategies and interventions to improve care and 
outcomes for patients with CKD.
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provinces and territories, and they would allow for eval-
uation of how the country compares with similar nations 
in CKD care. If combined with existing data sources (eg, 
administrative databases), data on CKD management 
in primary care might also facilitate efforts to integrate 
CKD management with care for other major NCDs (eg, 
diabetes, cardiovascular diseases (CVDs), hypertension, 
obesity).5
Effective and sustainable chronic disease care is depen-
dent on well-organised QI strategies to monitor processes 
of care and outcomes and to inform optimal care 
delivery.1 In the CKD domain, end-stage renal disease 
(ESRD) care has been the sole focus of national QI activ-
ities, often administered in conjunction with national/
regional registries (eg, Canadian Organ Replace-
ment Register, US Renal Data System, European Renal 
Registry).1 5 While there is no surveillance system for 
non-dialysis-dependent CKD in most countries, including 
Canada,5 13 a few have developed initiatives in this direc-
tion.14 1 5 13 15 A national CKD surveillance system using 
routinely collected practice data is feasible in nations with 
well-developed healthcare systems as CKD lends itself 
particularly well to surveillance because of its laborato-
ry-based diagnosis.16 Although healthcare is provincially/
territorially structured and administered in Canada, 
there are existing national networks and collaborations 
such as the Canadian Primary Care Sentinel Surveillance 
Network (CPCSSN)17 that can be important facilitators 
for national QI-based studies.
We set out to improve the understanding of how 
patients with CKD are managed and the variation across 
practitioners, regions and provinces to drive improve-
ments in care delivery. Our study is a multidisciplinary 
(nephrology, primary care) and cross-jurisdictional effort 
leveraging data from the CPCSSN to investigate the 
epidemiology and management of CKD in the Canadian 
primary care system. The overarching aim is to use data 
derived from primary care electronic medical records 
(EMRs) to identify gaps in care and to provide oppor-
tunities for interventions to improve care and patient 
outcomes.
objectives
1. Develop and validate a case definition for CKD in 
primary care and apply this to ascertain the burden of 
CKD in primary care, obtaining data on unidentified 
cases using standard criteria.18 19
2. Determine the current practice patterns on CKD risk 
identification in primary care by ascertaining whether 
high-risk groups (eg, individuals with diabetes, 
hypertension and urological disorders, as well as those 
with chronic use of nephrotoxic medications) are 
appropriately screened and managed for CKD.
3. Determine whether people with CKD are being 
managed based on established quality indicators 
and investigate the care variation across patients’ 
demographics (age, sex, socioeconomic status, rural/
urban residence, comorbidity burden), provider 
characteristics (family physician/nurse practitioner, 
year of graduation, rural/urban, individual/
group, fee for service) and regional characteristics 
(intraprovincial/territorial and interprovincial/
territorial variation, rural versus urban).
MeThods and analysis
setting
The CPCSSN17 20 21 is the first pan-Canadian multidis-
ease surveillance system. The data resource profiles and 
context within the Canadian health system are detailed 
elsewhere.22 Canada is considered a high-income country 
by the World Bank Classification Index with a population 
of 35 362 905 (2016). It is the second largest country 
in the world with a land area of 9 984 670 km2. It has 
a gross domestic product of $C1.634 trillion (2016), and 
about 10.1% of this is spent on healthcare. In Canada, 
healthcare is a provincial or territorial mandate under 
the oversight of the Canada Health Act and with a finan-
cial assistance from the federal government ensuring 
universal, publicly funded health services to the popu-
lation for medically necessary care including physician 
visits, hospitalisations and, in some provinces, universal 
drug coverage. Primary care is the first portal for accessing 
care particularly for routine chronic disease care.
The structure of CPCSSN comprised a network of 
12 practice-based primary care research networks 
that collect primary care health information from the 
EMRs of primary care providers (primary care practices 
(PCPs)) in eight out of the ten provinces and one out 
of the three territories in the country (figure 1). There 
are ~1200 sentinels (ie, participating PCPs) contributing 
data to the CPCSSN, which is updated quarterly. This 
actively expanding repository currently contains data on 
approximately 1.5 million Canadians. The initial focus of 
the CPCSSN was to conduct surveillance on five chronic 
conditions: diabetes, hypertension, osteoarthritis, chronic 
obstructive pulmonary disease and depression. Subse-
quently, it was expanded to included three neurological 
conditions: dementia, epilepsy and Parkinson’s disease. 
Our project team has been instrumental in working 
with CPCSSN to further expand on these conditions by 
including CKD, and this work on CKD will be conducted 
from January 2017 to December 2018. It will take place 
under the auspices of the Alberta’s Strategy for Patient 
Oriented Research (SPOR) Primary and Integrated 
Health Care Innovation Network (PIHCIN).
Population and data sources
Data for the CPCSSN database are extracted from the 
EMRs of participating sentinels, rendered anonymous, 
coded and processed using established frameworks 
described in detail elsewhere.21 23 The data are placed 
in regional network databases and then merged into 
the national repository. It is made available for surveil-
lance and research and increasingly for QI projects and 
for clinical decision support where available, through 
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Figure 1 Map of Canada showing CPCSSN networks distribution. CPCSSN, Canadian Primary Care Sentinel Surveillance 
Network.
the implementation of a patient reidentification tool 
held only within the custodial clinics themselves. With 
appropriate data sharing agreements with its sentinel 
PCPs, CPCSSN data may be linked with administrative 
health data for future work to follow-up on CKD-related 
outcomes (eg, ascertainment of progression to dialysis 
requirement using registry data).
The CPCSSN database will be used to develop a 
cohort of patients with CKD being managed in primary 
care between 1 January 2010 and 31 December 2015 
(baseline cohort) and from 1 January 2016 onwards 
(open cohort). The database is updated quarterly, 
allowing for identification of new patients with CKD 
who meet the inclusion criteria during the study period. 
The CPCSSN database contains patient information on 
sociodemographics (age, sex, socioeconomic status 
(calculated deprivation category)), treatment (medi-
cations data), laboratory results and comorbidities 
(table 1; figure 2).21 24 Patients under 18 years of age will 
be excluded from the cohorts, as will those diagnosed 
with ESRD and on dialysis or having renal transplant. 
We will leverage validated algorithms, case defini-
tions and guidelines to define CKD, at-risk population 
and processes of care measures based on established 
methods and criteria (table 2).25–27
Identification of cKd
The major focus is to validate a case definition for CKD 
in primary care using the CPCSSN repository to enable 
us to identify patients with CKD. We will leverage the 
existing frameworks and conventions by national and 
international CKD guidelines, as well as definitions used 
elsewhere.26 28 Serum creatinine (Scr) measurements 
will be used to calculate estimated glomerular filtration 
rate (eGFR) using CKD Epidemiology Collaboration 
equation.29 Individuals with at least one face-to-face PCP 
encounter and two calculated eGFR values <60 mL/min 
per 1.73 m2 more than 90 days apart or having an Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) 
diagnosis code for CKD used at least twice in an outpa-
tient encounter as of 31 December 2015, will be defined 
to have CKD. We recognise the significant limitations of 
the ICD-9 codes when applied for CKD identification in 
the community; however, its use will allow us to capture 
those patients with CKD who may or may not have had 
an abnormal eGFR, for example, cystic kidney diseases 
and other rare congenital disorders. In a secondary anal-
ysis, CKD will be defined by eGFR <45 mL/min/1.73 m2 
using two values of eGFR more than 90 days apart. This 
definition was selected because, although GFR <60 mL/
min/1.73 m2 constitutes CKD, individuals with GFR 
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Table 1 Data variables
Domain Variables
Patient
demographics and
clinical data
 ► Patient ID (unique patient number generated by CPCSSN)
 ► Sex
 ►Month and year of birth
 ► Occupation
 ► Highest education
 ► Housing status
 ► Postal code
 ► EMR status—active, deceased, duplicate, inactive, unknown
 ► Language
 ► Race/ethnicity
 ► Deceased tear
 ► Date created (date this record was created)
 ► Time since last visit—6, 12, 24 or 36 months
 ► CPCSSN conditions—yes/no for diabetes, depression, osteoarthritis, COPD, hypertension, dementia, Parkinson’s, 
epilepsy
 ► CPCSSN conditions—count (ie, numeric value)
 ► Disease case indicator—disease (diabetes, depression, osteoarthritis, COPD, hypertension, dementia, Parkinson’s, 
epilepsy)
 ► Disease case indicator—indicator type (billing, encounter diagnosis, health conditions, laboratory result (HbA1C, fasting 
glucose), medication)
 ► Disease case indicator—indicator value (numeric value of HbA1C and/or fasting glucose)
Patient–provider 
pairing
 ► Patient ID (unique patient number generated by CPCSSN)
 ► Provider ID (unique provider number generated by CPCSSN; primary provider of patient)
 ► Start date
 ► End date
Provider 
information
 ► Provider ID (unique provider number generated by CPCSSN)
 ► Sex
 ► Birth year
Billing data  ► Patient ID (unique patient number generated by CPCSSN)
 ► Date created
 ► Service date
 ► Diagnosis text—cleaned
 ► Diagnosis text—original
 ► Diagnosis code type (ie, ICD-9, ICD-10)
 ► Diagnosis code (ie, 401)
Clinical encounters  ► Patient ID (unique patient number generated by CPCSSN)
 ► Provider ID (unique provider number of the attending provider generated by CPCSSN)
 ► Encounter date
 ► Encounter type—academic clinic, community clinic
 ► Reason for visit—cleaned
 ► Reason for visit—original
Encounter 
diagnoses
 ► Patient ID (unique patient number generated by CPCSSN)
 ► Created date
 ► Diagnosis text—cleaned
 ► Diagnosis text—original
 ► Diagnosis code type (ie, ICD-9)
 ► Diagnosis code (ie, 401)
Physical 
examination data
 ► Patient ID (unique patient number generated by CPCSSN)
 ► Exam name—systolic BP, diastolic BP, height, weight, BMI, waist circumference, waist to hip ratio (all values)
 ► Result—cleaned numeric value
 ► Result—original numeric value
 ► Unit of measure
 ►Most recent value—yes, no
Health condition  ► Patient ID (unique patient number generated by CPCSSN)
 ► Created date
 ► Onset date
 ► Diagnosis text—cleaned
 ► Diagnosis text—original
 ► Diagnosis code type (ie, ICD-9)
 ► Diagnosis code (ie, 401)
Continued
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Domain Variables
Laboratory data  ► Patient ID (unique patient number generated by CPCSSN)
 ► Date performed
 ► Laboratory name—cleaned text (fasting glucose, glucose tolerance, HbA1C, HDL, LDL, total cholesterol, triglycerides, 
microalbumin, urine albumin to creatinine ratio, haemoglobin, creatinine, eGFR/GFR)
 ► Laboratory name—original text
 ► Laboratory result—numeric value
 ► Unit of measure
 ►Most recent value—yes, no
Medical/surgical 
procedure
 ► Patient ID (unique patient number generated by CPCSSN)
 ► Date created
 ► Date performed
 ► Procedure name—cleaned text
 ► Procedure name—original text
Medication records  ► Patient ID (unique patient number generated by CPCSSN)
 ► Start date
 ► Stop date
 ►Medication name—cleaned text
 ►Medication name—original text
 ►Medication code—ATC code (Anatomical Therapeutic Chemical classification system)
 ► Time since (initial prescription)
 ► DIN (drug identification number)
 ► Strength
 ► Dose
 ► Frequency
 ► Unit of measure
Referral data  ► Patient ID (unique patient number generated by CPCSSN)
 ► Date created
 ► Date completed
 ► Referral name—cleaned text
 ► Referral name—original text
Risk factor data  ► Patient ID (the unique patient number generated by CPCSSN)
 ► Date created
 ► Start date
 ► Stop date
 ►Most recent—yes, no
 ► Risk factor name—cleaned text (smoking, alcohol, diet, exercise, obesity)
 ► Risk factor name—original text
 ► Status—cleaned (current, never, n/a, not current, past, unknown)
 ► Status—original
 ► Value—cleaned
 ► Frequency
 ► Duration
 ► End
BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CPCSSN, Canadian Primary Care Sentinel 
Surveillance Network; eGFR, estimated glomerular filtration rate; EMR, electronic medical records; HbA1C, glycated haemoglobin 
concentration; HDL, high density lipoprotein; ICD, International Classification of Diseases; LDL, low density lipoprotein.
Table 1 Continued 
between 45 and 60 mL/min/1.73 m2 usually have favour-
able prognosis in the absence of proteinuria, and they are 
substantially fewer in number than those with GFR <45/
min/1.73 m2. Patients with eGFR <45 mL/min/1.73 m2 
are also a more attractive population for intervention due 
to higher risk of adverse clinical outcomes including risk 
of progression to ESRD.2 14 Validation of the primary care 
CKD case definition algorithm will consist of an expert 
blinded chart review and identification of cases in a 
random sample of 1000 CPCSSN charts, containing both 
original and cleaned text data from the EMRs for patients 
aged 18 years or older, and comparison with the outcome 
of an independent search of the same sample using the 
CPCSSN case finding algorithm. Analysis will consist of 
calculations of sensitivity, specificity and positive and 
negative predicted values. The prevalence of CKD stages 
3–5 will be presented as unadjusted prevalence estimates 
and weighted averages for population rates with 95% CIs 
using the census data and will be stratified by PCP, rural/
urban location and province or territory.
Evaluation of processes of care
The process-based outcomes (quality of care metrics) 
will be defined and evaluated using established methods 
across key domains of risk identification and case finding 
for CKD, as well as delivery of appropriate management 
including monitoring of risk factors for progression and 
CVD, and referral for specialist nephrology care where 
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Figure 2 The project concept.
necessary (table 2). We are specifically focusing on the 
key domains of CKD management in primary care that 
include:
 ► CKD risk identification. This entails the evaluation of 
the proportion of patients with risk factors (diabetes 
and/or hypertension) present for at least 1 year that 
are tested for CKD within the previous 12 months of 
follow-up.
 ► Identification of CKD. This is to determine the pro-
portion of patients with CKD (defined based on lab-
oratory measures) and/or correctly coded as having 
CKD in the EMR using defined clinical parameters.
 ► Management of CKD: This examines the current state 
of practice on the management of the common risk 
factors (blood pressure (BP), glycaemia, proteinuria, 
dyslipidaemia) associated with CKD progression and/
or risk of CKD. For example, ascertaining the propor-
tion of patients achieving guideline-concordant treat-
ment targets (BP, proteinuria, HbA1c).
 ► Appropriate referral. This is to capture the proportion 
of patients appropriately referred for specialist kidney 
care (defined by any visit to nephrologist or multidis-
ciplinary CKD clinic within the last 12 months) based 
on guideline-concordant criteria for referral.
data analysis
Covariates definition and evaluation of CKD markers
Sociodemographic, clinical, laboratory and medica-
tion data will be classified using standard definitions 
established by the CPCSSN.17 24 30–34 Other comorbid 
conditions relevant to the care of patients with CKD but 
not defined by the CPCSSN (coronary artery disease, 
stroke, peripheral vascular disease, heart failure) will be 
identified using standard procedures to search for those 
diagnoses in patients’ medical records (based on vali-
dated ICD-9-CM coding algorithms35). Baseline kidney 
function (using eGFR) will be calculated using all Scr 
measurements taken within a 6-month period of the first 
creatinine measurement, with the index eGFR defined 
as the mean of the 6-month measurements. Assessment 
of urine protein excretion will be estimated using the 
albumin to creatinine ratio based on spot urine measure-
ments using standard conventions.25 All CKD cases will 
be risk stratified, defined and classified according to 
current guideline recommendations.25 Demographic 
information (including age, sex and postal code) of those 
with and at risk of CKD will be extracted (tables 1 and 
2). Normally distributed variables will be summarised as 
means with SD, and non-normally distributed data will 
be summarised as medians with IQRs. Dichotomous data 
will be expressed in percentages. The representative-
ness of the study population will be tested by comparing 
their age and sex profiles to the population distribution 
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Figure 3 Project timeline/milestones.
Table 2 Elements of high-quality CKD care as defined by standard national and international CKD guidelines25 44–48
Domain Objective Measures
Identification of CKD 
risk factors
To establish an organised system for 
identification of people with risk factors 
and evaluated for the presence of CKD 
markers
Percentage of patients with risk factors* (present for at least 1 year) tested for 
CKD within the last 12 months
Identification of CKD To establish an organised system where 
people with CKD are appropriately 
identified
Proportion of patients with CKD correctly diagnosed and appropriately coded 
(validated based on KDIGO definition standard of using Scr measurements to 
derive eGFR <60 mL/min based on two measures at least 90 days apart based 
on CKD-EPI equation.
Management of 
CKD: Monitoring 
of risk factors for 
progression and CVD
To establish an organised system to 
ensure patients with CKD are receiving 
guideline-concordant care appropriate 
for the stage of CKD. This implies 
that those with early stages are being 
monitored appropriately in primary care.
Proportion of patients receiving appropriate testing and monitoring:
 ► Percentage of patients with urinary albumin tested within 6 months of index 
GFR <60 mL/min/1.73 m2
 ► Percentage of patients with index GFR <60 mL/min/1.73 m2 and diabetes 
mellitus who have glycated haemoglobin tested at least annually
 ► Frequency of eGFR and albuminuria testing in patients with a baseline of 
eGFR <60 mL/min and/or ACR of 70 mg/mmol (<1 year, 1–2 years, >2 years)
Proportion of patients receiving appropriate cardiovascular risk management:
 ► Percentage of patients >50 years of age and eGFR <45 mL/min and/or CVD 
history on a statin medication
 ► Percentage of patients with diabetes and proteinuria on an ACEi or ARB
 ► Percentage of patients with history of CVD on appropriate secondary 
prevention (aspirin, beta-locker, ACEi, statin)
Proportion of patients achieving treatment targets (BP, proteinuria, HbA1c).
 ► Percentage of patients with diabetes and/or proteinuria (ACR>70 mg/mmol) 
achieving a target BP of ≤130/80 mm Hg
 ► Percentage of patients with eGFR <60 mL/min achieving a target BP of 
≤140/90 mm Hg
 ► Percentage of patients with proteinuria (ACR>70 mg/mmol) achieving a 
target reduction to 50% of baseline
 ► Percentage of patients with diabetes achieving a target HbA1c~7%
Appropriate referral 
system
To develop a system where patients with 
CKD that need specialist input to care 
are appropriately identified and referred.
Proportion of patients appropriately referred for specialist care (defined by any 
visit to nephrologist or multidisciplinary CKD clinic within the last 12 months, 
for those patients that meet the KDIGO referral criteria)†
*Diabetes, hypertension, CVD, nephrotoxic medications (non-steroidal anti-inflammatory drugs, calcineurin inhibitors, lithium), certain 
urological disease (eg, kidney stones, prostatic hypertrophy), multisystem diseases (eg, lupus) and family history of kidney disease.
†This would include advanced stages of CKD (eGFR<30 mL/min/1.73 m2), significant albuminuria (ACR≥70 mg/mmol), rapid loss of eGFR 
(>15 mL/min/1.73 m2) refractory hypertension and history of acute kidney injury.
ACEi, ACE inhibitor; ACR, albumin to creatinine ratio; ARB, angiotensin-receptor blocker; BP, blood pressure; CKD, chronic kidney disease; 
CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EPI, Epidemiology Collaboration; HbA1c, glycated haemoglobin 
concentration; KDIGO, Kidney Disease Improving Global Outcomes; Scr, serum creatinine.
as reported in the Canadian 2011 Census (adjusting for 
2016 census data when available).
EthIcs And dIssEMInAtIon
The CPCSSN is committed to high ethical standards when 
handling individual patient data collected from EMRs of 
participating PCPs from across Canada. These data are 
aggregated and stored in CPCSSN’s central repository at 
the Centre for Advanced Computing, Queens University 
in Kingston, Ontario. There are well-developed organi-
sational, physical and technological safeguards at all 
levels (clinic, provincial, national) to ensure that the 
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privacy of patients is protected and that all collection, 
retention, use or disclosure of data complies with appli-
cable privacy legislation and ethical requirements.17 21 
All personal identifiers are removed from the data in the 
national research repository to protect patient confiden-
tiality.21 The protocol has undergone a scientific review 
and approval by the CPCSSN Surveillance and Research 
Standing Committee, and ethical approval for the study 
was granted by the University of Alberta Health Research 
Ethics Committee.
This project uses an integrated knowledge translation 
(KT) strategy, where relevant stakeholders (patients, 
practitioners, policy-makers) have been involved from 
inception (proposal development) to ensure that the 
project addresses the needs of patients and practitioners. 
The activities underpinning the Alberta SPOR PIHCIN 
centre on the patients are patient oriented, where the 
voices and perspectives of patients are solicited from 
research inception (eg, defining research questions) to 
completion. The patients are collaborators rather than 
research subjects, and we have a patient representative 
on the project team to ensure that patients’ voices and 
perspectives guide the work to completion and that it 
remains patient centred.
The involvement of the knowledge end-users (practi-
tioners and policy-makers) and the high priority that they 
place on the project will ensure that we drive it forward 
to completion and provide an opportunity to meaning-
fully change the way that care is delivered to patients with 
CKD managed in primary care. For example, after iden-
tifying regions/clusters with especially suboptimal CKD 
care, we will collaborate with providers, policy-makers 
and regional health authorities to improve care in those 
regions. We will apply the KT Canada Knowledge-to-Ac-
tion Cycle Framework and other established methods 
(eg, PDSA (Plan, Do, Study, Act) concept) to disseminate 
our findings to all relevant stakeholders and end-users 
for action.36 37 We will leverage our collaborations with 
existing platforms and research networks such as the 
Canadian Society of Nephrology, CANN-NET (CAna-
dian KidNey KNowledge TraNslation and GEneration 
NeTwork), Can-SOLVE CKD (Canadians Seeking Solu-
tions and Innovations to Overcome Chronic Kidney 
Disease) and the countrywide PIHCIN to ensure the 
translation of our findings across provinces and territo-
ries, as well as internationally through our associations 
with the International Society of Nephrology and the 
Kidney Disease Improving Global Outcomes team.5 38 The 
results will be published in general medicine, nephrology 
and primary care peer-reviewed journals and presented 
at relevant national and international scientific meetings. 
A performance report will be produced against the indi-
cators relevant to each objective, aggregated by practice 
sentinel, to highlight practice performance and map out 
areas for improvement, critical for continuing profes-
sional development of PCPs and helping to enhance CKD 
management in primary care. In the future, this data-
base with be linked to the Canadian Organ Replacement 
Registry and relevant provincial administrative databases 
to study clinically relevant outcomes of risk and progres-
sion toikidney failure (ESRD) and adverse cardiovascular 
outcomes39 40 (figure 3).
This work will close the information gap between 
observed and expected burdens and risks of CKD and 
map out standards of care achieved, providing oppor-
tunities for focused and effective population-level QI 
strategies and other service improvement initiatives. This 
project will demonstrate proof of concept for an early 
identification and management of CKD programme in 
primary care, and this will provide the basis for devel-
oping relevant policies and KT strategies to enhance 
the uptake of findings—for people with CKD and other 
chronic diseases as well. The work will facilitate identifica-
tion and appropriate management of patients with CKD 
at high risk of progression to ESRD. The findings will be 
reported based on existing reporting frameworks.41
We have anticipated potential threats and have devised 
strategies to mitigate them. The first is related to feasibility 
within the defined timeframe (figure 3). This is unlikely 
to hinder the success of the project as we have completed 
significant preliminary work for data access, and the team 
has considerable experience with the use of this kind of 
data for policy-relevant research.5 19 36 42 43 Second, limita-
tions general to the use of EMR data in research are 
acknowledged. The collated information is based on clin-
ical encounters and needs and, thus, may be missing for 
some important key variables, and data quality may vary 
by region and/or sentinel; specifically, data on patients’ 
priorities and satisfaction of care are rarely collated in a 
clinical setting. However, most important demographic, 
clinical and laboratory information needed for this study 
are well captured in the existing platform chosen for this 
work. Third, lack of use of patient-reported outcomes 
measures such as satisfaction with care, self-management 
support and so on could not be included as these were 
not routinely collated in this database.
In summary, planning, development and implementa-
tion of nephrology services require reliable information 
systems and databases to capture information on trends in 
disease burden, processes of care and related outcomes. 
In the absence of national/regional health information 
systems, one way to achieve this is by the creation of 
surveillance systems using routine practice data, such as 
the CPCSSN and those established specifically for CKD 
in other jurisdictions across the world44–48 (table 3). The 
established conventions and guidelines on CKD can be 
leveraged for systematic case definition and evaluation of 
quality of care across settings. This can be facilitated by vali-
dation as well as enactment of quality metrics to measure 
the processes, quality of care and related outcomes and to 
generate uniformity across databases which may permit 
analyses across countries and regions. It is important to 
detect CKD early enough to be able to implement effec-
tive interventions. Ongoing primary care management 
of key risk factors for CKD (eg, hypertension, vascular 
disease, diabetes) is likely one effective strategy to reduce 
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progression of CKD and to reduce adverse complica-
tion rates. Early detection and treatment of CKD and 
reducing adverse events with appropriate medications 
also reduces the morbidity and cost of CKD and related 
complications. The work described in this protocol there-
fore has a huge potential to address the identified gaps 
for optimal care delivery of CKD at the primary care level 
that would impact positively on patients’ outcomes and 
health system improvement.
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